Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female Subjects able to give consent~* Post partum patients~* Baseline Hgb \< /= 10 g/dL~* Agree to practice birth control~Exclusion Criteria:~* Participation in previous clinical trial of this investigational agent~* Known hypersensitivity reaction to active control~* Significant vaginal bleeding~* History of anemia other than iron deficiency anemia~* Anticipated need for surgery during the study~* Active severe infection or malignancy~* Known positive Hepatitis B antigen of Hepatitis C viral antibody~* Known HIV antibodies~* Received an investigational drug within 30 days of screening~* Alcohol abuse within past 6 months~* Hemochromatosis or other iron storage disorders~* Significant cardiovascular disease~* Any laboratory abnormality, medical condition or severe psychiatric disorder which in the opinion of the investigator woud put the subject's disease management at risk or may result in the subject being able to comply with the study requirements

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric Carboxymaltose (FCM) (Type: EXPERIMENTAL): Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
- Ferrous Sulfate tablets (Type: ACTIVE_COMPARATOR): 325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).